CI

At a glance

ClinicalIndex Comparison Record
Phase 2Completed· 20 enrolled
Drug / intervention
erlotinib hydrochloride +2 moredrug
Likely dose
Not stated in record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.

Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.

Search/NCT00376948
NCT00376948Phase 2Completed

Phase II Trial of Novasoy®, Gemcitabine, and Erlotinib in Locally Advanced or Metastatic Pancreatic Cancer

Barbara Ann Karmanos Cancer Institute·interventional·Posted Sep 15, 2006·Updated Mar 1, 2021

In Brief

A Phase 2 clinical trial evaluating genistein, erlotinib hydrochloride, and 1 other intervention for Pancreatic Cancer. Completed, enrolled 20 participants across 2 sites.

Detailed Summary

RATIONALE: Drugs used in chemotherapy, such as gemcitabine, work in different ways to stop the growth of tumor cells, either by killing the cells or by stopping them from dividing. Erlotinib may stop the growth of tumor cells by blocking some of the enzymes needed for cell growth. Genistein may help gemcitabine and erlotinib kill more tumor cells by making tumor cells more sensitive to the drugs. PURPOSE: This phase II trial is studying how well giving genistein together with gemcitabine and erlotinib works in treating patients with locally advanced or metastatic pancreatic cancer.

Study Details

Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
CountriesUnited States

Timeline

Phase 2CompletedFinished
20052006200720082009201020112012201320142015201620172018201920202021202220232024202520262027
First PostedSep 15, 2006
Enrollment StartMay 1, 2005
Primary CompletionMar 1, 2010
TodayJul 2, 2026
Enrollment to primary: 4.8 yearsPosted 19.8 years ago

Interventions

genisteindietary

erlotinib hydrochloridedrug

gemcitabine hydrochloridedrug